NCT05601778View on ClinicalTrials.gov

A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis

PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

March 29, 2024

Study Completion Date

June 7, 2024

Conditions
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Interventions
DRUG

HSK31858

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis

DRUG

placebo

the placebo comparator of study

Trial Locations (1)

Unknown

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY